IBDEI30L ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,50535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50535,1,3,0)
 ;;=3^Nicotine Dependence,Unspec,Uncomplicated
 ;;^UTILITY(U,$J,358.3,50535,1,4,0)
 ;;=4^F17.200
 ;;^UTILITY(U,$J,358.3,50535,2)
 ;;=^5003360
 ;;^UTILITY(U,$J,358.3,50536,0)
 ;;=F19.20^^219^2454^15
 ;;^UTILITY(U,$J,358.3,50536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50536,1,3,0)
 ;;=3^Psycoactive Substance Dependence,Uncomplicated
 ;;^UTILITY(U,$J,358.3,50536,1,4,0)
 ;;=4^F19.20
 ;;^UTILITY(U,$J,358.3,50536,2)
 ;;=^5003431
 ;;^UTILITY(U,$J,358.3,50537,0)
 ;;=F43.11^^219^2454^12
 ;;^UTILITY(U,$J,358.3,50537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50537,1,3,0)
 ;;=3^PTSD,Acute
 ;;^UTILITY(U,$J,358.3,50537,1,4,0)
 ;;=4^F43.11
 ;;^UTILITY(U,$J,358.3,50537,2)
 ;;=^5003571
 ;;^UTILITY(U,$J,358.3,50538,0)
 ;;=F43.12^^219^2454^13
 ;;^UTILITY(U,$J,358.3,50538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50538,1,3,0)
 ;;=3^PTSD,Chronic
 ;;^UTILITY(U,$J,358.3,50538,1,4,0)
 ;;=4^F43.12
 ;;^UTILITY(U,$J,358.3,50538,2)
 ;;=^5003572
 ;;^UTILITY(U,$J,358.3,50539,0)
 ;;=F43.10^^219^2454^14
 ;;^UTILITY(U,$J,358.3,50539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50539,1,3,0)
 ;;=3^PTSD,Unspec
 ;;^UTILITY(U,$J,358.3,50539,1,4,0)
 ;;=4^F43.10
 ;;^UTILITY(U,$J,358.3,50539,2)
 ;;=^5003570
 ;;^UTILITY(U,$J,358.3,50540,0)
 ;;=L40.2^^219^2455^1
 ;;^UTILITY(U,$J,358.3,50540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50540,1,3,0)
 ;;=3^Acrodermatitis Continua
 ;;^UTILITY(U,$J,358.3,50540,1,4,0)
 ;;=4^L40.2
 ;;^UTILITY(U,$J,358.3,50540,2)
 ;;=^5009162
 ;;^UTILITY(U,$J,358.3,50541,0)
 ;;=L03.91^^219^2455^2
 ;;^UTILITY(U,$J,358.3,50541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50541,1,3,0)
 ;;=3^Acute Lymphangitis,Unspec
 ;;^UTILITY(U,$J,358.3,50541,1,4,0)
 ;;=4^L03.91
 ;;^UTILITY(U,$J,358.3,50541,2)
 ;;=^5009068
 ;;^UTILITY(U,$J,358.3,50542,0)
 ;;=L23.9^^219^2455^3
 ;;^UTILITY(U,$J,358.3,50542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50542,1,3,0)
 ;;=3^Allergic Contact Dermatitis
 ;;^UTILITY(U,$J,358.3,50542,1,4,0)
 ;;=4^L23.9
 ;;^UTILITY(U,$J,358.3,50542,2)
 ;;=^5009125
 ;;^UTILITY(U,$J,358.3,50543,0)
 ;;=L03.90^^219^2455^4
 ;;^UTILITY(U,$J,358.3,50543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50543,1,3,0)
 ;;=3^Cellulitis,Unspec
 ;;^UTILITY(U,$J,358.3,50543,1,4,0)
 ;;=4^L03.90
 ;;^UTILITY(U,$J,358.3,50543,2)
 ;;=^5009067
 ;;^UTILITY(U,$J,358.3,50544,0)
 ;;=L02.91^^219^2455^7
 ;;^UTILITY(U,$J,358.3,50544,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50544,1,3,0)
 ;;=3^Cutaneous Abscess,Unspec
 ;;^UTILITY(U,$J,358.3,50544,1,4,0)
 ;;=4^L02.91
 ;;^UTILITY(U,$J,358.3,50544,2)
 ;;=^5009016
 ;;^UTILITY(U,$J,358.3,50545,0)
 ;;=L30.2^^219^2455^8
 ;;^UTILITY(U,$J,358.3,50545,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50545,1,3,0)
 ;;=3^Cutaneous Autosensitization
 ;;^UTILITY(U,$J,358.3,50545,1,4,0)
 ;;=4^L30.2
 ;;^UTILITY(U,$J,358.3,50545,2)
 ;;=^5009155
 ;;^UTILITY(U,$J,358.3,50546,0)
 ;;=L30.9^^219^2455^10
 ;;^UTILITY(U,$J,358.3,50546,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50546,1,3,0)
 ;;=3^Dermatitis,Unspec
 ;;^UTILITY(U,$J,358.3,50546,1,4,0)
 ;;=4^L30.9
 ;;^UTILITY(U,$J,358.3,50546,2)
 ;;=^5009159
 ;;^UTILITY(U,$J,358.3,50547,0)
 ;;=Z48.01^^219^2455^5
 ;;^UTILITY(U,$J,358.3,50547,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50547,1,3,0)
 ;;=3^Change/Removal of Surgical Wound Dressing
 ;;^UTILITY(U,$J,358.3,50547,1,4,0)
 ;;=4^Z48.01
 ;;^UTILITY(U,$J,358.3,50547,2)
 ;;=^5063034
 ;;^UTILITY(U,$J,358.3,50548,0)
 ;;=L98.3^^219^2455^11
 ;;^UTILITY(U,$J,358.3,50548,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50548,1,3,0)
 ;;=3^Eosinophilic Cellulitis
